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Abstract
Type-1 diabetes (T1D) is an autoimmune disease in which insulin-secreting pancreatic beta cells are destroyed by the
immune system. An emerging strategy to regenerate beta-cell mass is through transdifferentiation of pancreatic alpha cells
to beta cells. We previously reported two small molecules, BRD7389 and GW8510, that induce insulin expression in a mouse
alpha cell line and provide a glimpse into potential intermediate cell states in beta-cell reprogramming from alpha cells.
These small-molecule studies suggested that inhibition of kinases in particular may induce the expression of several beta-
cell markers in alpha cells. To identify potential lineage reprogramming protein targets, we compared the transcriptome,
proteome, and phosphoproteome of alpha cells, beta cells, and compound-treated alpha cells. Our phosphoproteomic
analysis indicated that two kinases, BRSK1 and CAMKK2, exhibit decreased phosphorylation in beta cells compared to alpha
cells, and in compound-treated alpha cells compared to DMSO-treated alpha cells. Knock-down of these kinases in alpha
cells resulted in expression of key beta-cell markers. These results provide evidence that perturbation of the kinome may be
important for lineage reprogramming of alpha cells to beta cells.
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Introduction
Type-1 diabetes (T1D) is a chronic autoimmune disease
affecting 35 million patients worldwide. In T1D, insulin-secreting
pancreatic beta cells are destroyed by autoreactive immune cells
[1,2]._ENREF_1 The most common treatment for T1D is daily
injection of insulin; however, this treatment cannot always ensure
optimal glucose homeostasis, leading to complications such as
blindness, heart disease, limb amputation, and ultimately death
[3]. Another therapeutic strategy involves transplantation of
pancreatic islets [4] via infusion through the portal vein into the
liver, but high cost [5], limited donor availability, and beta-cell
toxicity [6,7] of immunosuppressive drugs severely restrict the use
of this treatment protocol.
Since T1D is characterized by extreme loss of beta-cell mass,
replenishing the beta-cell population by converting other pancre-
atic cell types, such as alpha cells, to beta cells may be a viable
therapeutic strategy [8,9]. For example, lineage reprogramming of
pancreatic alpha cells to beta cells by ectopic expression of
transcription factor, Pax4, has been shown to restore normogly-
cemia in mouse models of diabetes [10]. An alternative, and
potentially more therapeutically promising, approach for lineage
reprogramming involves the use of small molecules. This
approach, which we term chemical transdifferentiation [11], is
potentially safer, as it does not require viral delivery, and offers
greater dosage and temporal control. However, identification of
proteins or pathways that can be targeted for chemical
transdifferentiation requires knowledge of the similarities and
differences in the molecular and physiological architecture of the
initial state and the final, transdifferentiated state.
To gain such knowledge, we compared the transcriptomes and
proteomes of alpha and beta cell lines. In addition to analyzing the
basal state in cell culture, we also used two small molecules,
BRD7389 and GW8510, that we previously discovered to induce
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insulin expression in alpha cells (Figure S1 in File S1) [12,13].
BRD7389 and GW8510 inhibit several kinases, such as the RSK
family and CDK2, suggesting that lineage reprogramming of
alpha cells to insulin-producing cells may involve downregulation
of specific phosphorylated proteins in alpha cells. We reasoned
that a signature of such phosphorylated proteins would be its
presence at a higher level in alpha cells compared to beta cells;
further, BRD7389 and GW8510 treatment of alpha cells should
lower the levels of such phosphorylated proteins, as the alpha cells
progress towards an intermediary cell state. To identify phospho-
proteins with these signatures, we compared the phosphopro-
teomes of alpha and beta cell lines, and also examined the
alterations in the phosphoproteomes of alpha cell line upon
treatment with either BRD7389 or GW8510.
We identified two proteins, BR serine/threonine kinase 1
(Brsk1) and calcium/calmodulin-dependent protein kinase kinase
2 (Camkk2), which were each phosphorylated at higher levels for
specific phosphosites in alpha cells as compared to those in beta
cells. Moreover, both BRD7389 and GW8510 treatment of alpha
cells led to decreased phosphorylation at these phosphosites for
both proteins. Knock-down of either kinase was sufficient to
induce mRNA and protein expression of beta-cell markers,
including insulin, in alpha cells. Furthermore, inhibitors of
Camkk2 pathway induced beta-cell markers in alpha cells. These
studies highlight the importance of fully characterizing cell states
using both genetic and proteomic technologies in developing a
cellular reprogramming strategy.
Materials and Methods
Cell culture and reagents
Mouse pancreatic cell lines aTC1 and bTC3 were obtained
from ATCC and cultured at 37uC and 5% CO2 in low-glucose
(1 g/L) DMEM supplemented with 10% fetal bovine serum
(Hyclone), 50 U/mL penicillin and 50 mg/mL streptomycin.
Media was changed every 3–4 days. KN62 and KN93 were
obtained from Sigma-Aldrich.
Microarray analyses
GenePattern was used to perform Gene Set Enrichment
Analysis (GSEA) on previously reported data [14], using the gene
set database c2.all.v3.0.symbols.gmt, chip platform mouse
430a_2.chip, and 1000 permutations. GENE-E [15] was used
for comparative marker selection, and to generate the heat map.
The data are available as GEO accession number GSE36379.
Cell mitochondrial respiration and glycolytic activity
aTC1 cells were treated with 0.1% DMSO or 0.85 mM
BRD7389 for 3 days. Cells were seeded at 40,000/well into
polyornithine pre-coated 96-well cell culture plates from Seahorse
Bioscience. Seahorse Bioscience XF-96 extracellular flux analyzer
was used to measure OCR and ECAR over time and analyte
addition. Cell glycolytic activity was assessed by adding 10 mM
glucose at 34 min, while the maximum glycolytic activity was
induced with 5 mM oligomycin at 55 min. Glycolytic reserve was
determined by adding the glucose analogue 2-deoxyglucose
(100 mM) into the cell media at 76 min. Mitochondrial respiration
was assessed by adding: 1 mM oligomycin into the media at
34 min, 1 mM of the ionophore CCCP, and a combination of
5 mM rotenone and 5 mM antimycin A at 76 min. aTC1 cells
media contained 0.1% DMSO.
SILAC experiments
aTC1 and bTC3 and cells were cultured in low-glucose (1 g/L)
DMEM media (custom preparation from Caisson Laboratories)
that was deficient in L-arginine and L-lysine. DMEM media was
supplemented with 10% dialyzed FBS (Sigma-Aldrich), penicillin,
streptomycin, glutamine, and either L-arginine (Arg 0) and L-
lysine (Lys 0), L-arginine 13C6-HCL (Arg 6) and L-lysine-4,4,5,5d4
(Lys 4), or L-arginine 13C6-
15N4-HCl (Arg 10) and L-lysine
13C6,
15N2-HCl (Lys 8) (Sigma-Aldrich). To achieve .95% SILAC
amino acid incorporation, cells were grown for 25 days. For alpha
and beta cell comparison experiments, aTC1 cells were grown in
heavy state (R10K8), bTC3 were grown in light state (R0K0), and
the medium state (R6K4) contained a 1:1 mix of aTC1 and bTC3
cells. These experiments were completed in biological replicates
with SILAC label swapping. After compound treatment, cells were
washed with 1x PBS.
Cells were lysed at 4uC using a buffer containing 8 M urea,
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 mg/ml
aprotinin (Sigma-Aldrich), 10 mg/ml leupeptin (Roche), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 mM NaF, 2 mM
Na3VO4, 50 ng/ml calyculin A (Calbiochem), phosphatase
inhibitor mixture 1 (1/100, Sigma) and phosphatase inhibitor
mixture 2 (1/100, Sigma). Cellular lysates were spun down at
20,0006g at 4uC to remove insoluble material. Protein concen-
trations were determined using a bicinchoninic acid (BCA) protein
assay (Pierce) and corresponding SILAC samples were combined
in equal ratio. Approximately 5 mg of protein was used per
SILAC state. Proteins were reduced with 5 mM dithiothreitol and
subsequently alkylated with 10 mM iodoacetamide. Prior to
digestion, samples were diluted 1:4 with 50 mM Tris-HCl
pH 7.5. Proteins were digested with sequencing grade modified
trypsin (Promega) using an enzyme-to-substrate ratio of 1:50
overnight at 25uC. Samples were acidified with 0.5% formic acid
and subsequently desalted using a 500 mg tC18 Sep-Pak SPE
cartridge (Waters) as previously described [16].
Non-phosphorylated and phosphorylated peptides were pre-
pared as previously described [16]. Briefly, peptides were
fractionated offline by strong cation exchange (SCX) chromatog-
raphy on an Akta Purifier 10 system (GE Healthcare) using a
polysulfoethyl A strong cation exchange (SCX) column from
PolyLC (25069.4 mm, 5 mm particle size, 200 A pore size). A
160 min gradient was utilized for the fractionation with using
7 mM KH2PO4, pH 2.65, 30% MeCN as solvent A and 7 mM
KH2PO4, pH 2.65, 350 mM KCl, 30% MeCN as Solvent B. For
proteome analyses 5% of each SCX fraction was aliquoted, and
fractions were combined into 24 proteome samples that were
subsequently desalted using StageTips.[17] For phosphoproteome
analysis, 95% of each SCX fraction was used, and the SCX
fractions were combined into 12 phosphopeptide samples. All
SCX fractions were subsequently desalted with reversed phase
tC18 SepPak columns.
Phosphopeptide enrichment was completed using immobilized
metal affinity chromatography (IMAC) as previously described
[16]. Briefly, peptides were reconstituted in 200 ml of 40% MeCN,
0.1% formic acid and incubated for with 10 ml of packed Phos-
Select beads (Sigma) for 1 hr. Subsequently, IMAC beads were
loaded on C18 StageTips, washed twice with 40% MeCN, 0.1%
formic acid and once with 50 ml 1% formic acid. Phosphorylated
peptides were then transeluted to the C18 portion of the StageTip
by washing with 70 ml of 500 mM K2HPO4 (pH 7.0) three times.
StageTips were then washed with 50 ml of 1% formic acid and
peptides were eluted with 80 ml of 50% MeCN/0.1% formic acid
and dried to completeness.
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Peptide samples were reconstituted in 3% MeCN/1% formic
acid analyzed by LC-MS/MS using an Agilent 1200 LC coupled
online to an LTQ Orbitrap Velos mass spectrometer (Thermo
Fisher Scientific). Peptides were loaded onto a fused-silica capillary
column (New Objective) packed in-house with 14 cm of C18
reversed phase media (3 mm ReproSil-Pur C18-AQ media, Dr.
Maisch GmbH) and eluted into the mass spectrometer using a
70 min linear gradient (,0.29%B/min) from 10% solvent A
(0.1% formic acid) to 30% solvent B (0.1% formic acid/90%
acetonitrile). The mass spectrometer was operated in the data
dependent mode where an MS1 scan (R= 60 K) was acquired
with the Orbitrap analyzer followed by acquisition of CID MS/
MS scans with the iontrap analyzer on the top 16 most abundant
ions. An MS1 ion target of 16106 ions and an MS2 target of
16104 ions were utilized for acquisition. The maximum ion time
was set to 1 s for MS1 scans and set to 100 ms for MS/MS scans.
The dynamic exclusion time was 120 s, the repeat count was set to
2, and the repeat duration was set to 20 s. Monoisotopic precursor
selection and non-peptide monoisotopic recognition functions
were enabled.
All proteome and phosphoproteome data were processed
together using the MaxQuant software package v1.0.13.13 and
searched against the International Protein Index protein sequence
database (IPI version 3.70, mouse). For searching, the enzyme
specificity was set to trypsin, the number of missed cleavages was
set to 2, and the MS/MS tolerance was set to 0.5 Da. Oxidation of
methionines, N-terminal protein acetylation, and phosphorylation
of serines, threonines, and tyrosines were searched as variable
modifications, while carbamidomethylation of cysteines was
searched as a fixed modification. Peptides harboring oxidized
methionines or N-terminal acetylations were used for protein
quantification. Log2 SILAC ratios of bTC3 versus aTC1 cells
followed a normal distribution that was fitted using least-squares
regression. Mean and standard deviation values derived from the
gaussian fit were used to calculate p-values.
The peptide and protein false discovery rate (FDR) was set to
0.01 and the site FDR was set to 1. Phosphosite localization was
completed as described in Mertins et al. [18].
siRNA experiments
Mouse Brsk1 and Camkk2 Gene Solution siRNAs (Qiagen) were
used to perform the gene knock-down experiments. Quantitect
primer sets for each gene were used to determine gene expression.
Mouse aTC1 cells were plated in 96-well Corning (3340) plates at
40,000 cells/well in 100 mL DMEM. 0.3 mL/well Lipofectami-
neTM RNAiMAX (Invitrogen) and Opti-MEM Media was used
to transfect the mix of 4 different siRNA constructs into cells. Cells
were incubated in transfection mix for 6 h at 37uC, before
changing to fresh media. Cells were cultured for 3 days, followed
by qPCR or immunohistochemistry. Statistical significance was
determined using t-test.
shRNA experiments
The different shRNA lentiviruses were obtained from the RNAi
Consortium (TRC; http://www.broadinstitute.org/rnai/public/)
in 96-well format, with approximately 108 viral particles/mL per
Figure 1. Experimental design for comparative analyses of pancreatic alpha and beta cells using chemical probes, gene-expression
analysis, and mass spectrometry-based quantitative phosphoproteomics. (A) Computational prediction and experimental validation of
phenotypic differences between mouse alpha cells (aTC1) and beta cells (bTC3) using comparative gene-expression analysis. (B) Workflow for
quantitative proteomic and phosphoproteomic analysis of alpha and beta cells, and alpha cells treated with BRD7389 and GW8510. (C) Outline of
SILAC conditions upon which quantification was performed. These analyses generated a candidate list of kinases differentially expressed in alpha and
beta cells from which target kinases were identified using knockdown, chemical genetics, and immunocytochemistry.
doi:10.1371/journal.pone.0095194.g001
Endocrine-Cell Phosphoproteomics
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well. Hairpin identities are listed in Table S1 in File S1. Mouse
aTC1 cells were plated in 96-well Corning (3340) plates at 40,000
cells/well in 100 mL standard culture media. The next day,
polybrene was added to each well (6 mg/mL), and cells were spin-
infected with 1 mL virus at 2,250 rpm for 30 min at 30uC. Media
was changed 4 h later to fresh media. The next day, media
containing 1 mg/mL puromycin was added. Puromycin-supple-
mented media was changed every 3 days. After 10 days in culture,
cells were lysed and mRNA extracted using Qiagen RNeasy 96
Kit. Statistical significance was determined using t-test.
Immunocytochemistry
Cells were fixed with 4% PFA for 15 min, followed by a 0.2%
Triton-X-100 permeabilization for 20 min, and blocking with PBS
supplemented with 2% BSA for 2 h. Fixed cells were then
incubated with a mix of 1:200 rabbit anti-Pdx1 (Abcam) and 1:500
Figure 2. Gene-expression analysis of alpha and beta cell lines reveals higher metabolic activity in the alpha cell line. Gene sets with
increased expression in (A) alpha or (B) beta cell lines were identified by performing gene-set enrichment analysis (GSEA) on gene-expression
profiling data, resulting in an enrichment score profile for each gene set (green line). Individual members of each gene set (vertical black bars) are
enriched in either alpha cells (blue) or beta cells (red). To validate the predicted differences in cellular respiration between alpha and beta cells, we
determined (C) extracellular acidification rate (ECAR) and (D) oxygen consumption rate (OCR) of alpha cells (red), BRD7389-treated alpha cells (black),
bTC3 cells (blue), and INS-1E cells (brown). Glucose (Glu), oligomycin (Oligo), 2-deoxyglucose (DOG), CCCP, and rotenone/antimycin A (Rot/Ant) were
added at the indicated times. Data represent the average and standard deviation of 18 biological replicates.
doi:10.1371/journal.pone.0095194.g002
Endocrine-Cell Phosphoproteomics
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guinea pig anti-insulin (Sigma) overnight at 4uC. As secondary
antibodies, AlexaFluor594 anti-rabbit and AlexaFluor488 (Invi-
trogen) anti-guinea pig were used. Images were acquired on an
ImageXpress Micro automated microscope (Molecular Devices).
Exposure settings: 600 ms for Pdx1 (TxRed), 200 ms for insulin
(FITC), and 8 ms for DAPI. Statistical significance was deter-
mined using t-test.
Gene expression
Total mRNA from siRNA and compound-treated cells were
extracted with Qiagen RNeasy Plus Mini Kit. qPCRs were
performed with Power SybrGreen PCR Master Mix and an
Applied Biosystems 7900HT plate reader. Mouse primers were
obtained from IDT and are listed in Table S2 in File S1.
Results
Experimental strategy and rationale
We were interested in comparing the genetic and proteomic
levels of various transcription factors in alpha and beta cells, as
such proteins are linked with lineage reprogramming. Thus, we
compared the gene-expression profiles of the mouse alpha-cell
(aTC1) and beta-cell (bTC3) lines (Figure 1A). In parallel, we
compared the proteomes and phosphoproteomes of alpha cells
and beta cells using stable isotope labeling by amino acids in cell
culture (SILAC; Figure 1B) [19–21]. We used a three-state
labeling strategy, with two states corresponding to the individual
cell populations, and the third state corresponding to a mixed
proteome from alpha and beta cells. This approach enabled four
protein intensity measurements for alpha cells and beta cells using
only two replicates (Figure S2 and S3 in File S1). We analyzed the
phosphoproteomes of alpha cells and beta cells by enrichment of
phosphopeptides using immobilized metal-affinity chromatogra-
phy (Figure 1B), and also determined the changes in the
phosphoproteome of alpha cells upon treatment with BRD7389
(1 h, 120 h) or GW8510 (120 h) (Figure 1C).
Transcriptome analysis and phenotypic studies
We used previously described gene-expression profiling data
[14], where the transcript levels of ,14,000 genes of alpha and
beta cells were determined using GeneChip Mouse Genome 430A
arrays (Affymetrix). A similar comparison of alpha and beta cell
transcriptomes has been reported, using cell sorting of primary
human islets [22]. To identify the genes most differentially
expressed between alpha cells and beta cells, we used comparative
marker selection [23], which employs statistical approaches such
as false-discovery rate (FDR) and family-wise error rate (FWER) to
account for multiple-hypothesis testing. From these top genes, we
identified the transcription factors that were differentially ex-
pressed in alpha cells and beta cells (Figure S4 in File S1). A
number of transcription factors known to be involved in alpha-
and beta-cell specification were identified, including Pdx1, Mnx1,
and Irx1. To examine the pathways involved with differentially
expressed genes, we used gene-set enrichment analysis (GSEA)
[24,25], which determines whether a pre-defined set of genes
shows statistically significant, concordant differences between two
biological states (Figure 2A, B). We found that, among other gene
sets, genes corresponding to oxidative phosphorylation, hypoxia,
branched-chain amino acid catabolism, and electron transport
were enriched in alpha cells (Figure 2A, Table S3 in File S1). In
beta cells, gene sets corresponding to membrane trafficking and
antigen presentation and processing were enriched (Figure 2B,
Table S4 in File S1).
Since GSEA suggested that the alpha cell line may have a
higher metabolic rate than beta cells, we compared the
mitochondrial respiration and glycolytic activity in aTC1 cells,
BRD7389-treated aTC1 cells, and two beta cell lines: bTC3 and
INS-1E cells. We observed higher glycolysis rate, maximum
glycolytic capacity, and glycolytic reserve in aTC1 cells, as
measured by extracellular acidification rate (Figure 2C, S5 in File
S1). We also determined mitochondrial respiration in cell
populations by quantifying extracellular oxygen consumption
rates (OCR) in the presence of various mitochondrial inhibitors
[26]. aTC1 cells had elevated basal respiration rates, energy
coupling efficiency, and maximum respiration rate compared to
the beta cell lines (Figure 2D). Further, treatment of aTC1 cells
with BRD7389 led to a decrease in the overall glycolytic activity
and mitochondrial respiration rates, a phenotype reminiscent of
the beta cell lines (Figure 2D) [27–30], further supporting the
hypothesis that BRD7389 directs alpha cells towards an interme-
diate cell state.
Proteome and PTM coverage and analysis
We performed quantitative proteomics on the alpha cells,
compound-treated alpha cells, and beta cells using SILAC [19–
21]. Briefly, cells were cultured in media with amino acids
containing light, medium, or heavy isotopes of arginine and lysine.
Cell lysates from these three SILAC states were mixed and
proteins were reduced, alkylated, and digested with trypsin. The
SILAC media (e.g., light, medium, or heavy) from which each
observed tryptic peptide originates determines the isotopic label
state of the lysine or arginine residue in each peptide. The peptides
were subsequently fractionated using strong cation exchange
chromatography and phosphopeptides were enriched using
immobilized metal-ion chromatography, where phosphopeptides
chelate to a bead-immobilized iron (III) complex. Protein ratios
were determined from the Protein Groups table generated by the
MaxQuant [31,32] software package v1.0.13.13. Two indepen-
dent SILAC triple-labeling experiments were completed for both
the proteome and phosphoproteome analyses of alpha cells and
beta cells, with Pearson correlation coefficient r = 0.9 between
replicates (Figure S3 in File S1). In total, 3,250 proteins and 9,978
Table 1. Summary of proteomic studies.
No. of proteins quantified No. of proteins ratios with p,0.01 and .3-fold change
Total proteome 3250 306
No. of peptides quantified No. of proteins ratios with p,0.01 and .6-fold change
pSTY peptides 9979* 1056
*including 467 phosphorylated kinase peptides.
Total proteome results based on 24 SCX fractions over two SILAC experiments. pSTY peptide results are based on 12 SCX fractions over two SILAC experiments.
doi:10.1371/journal.pone.0095194.t001
Endocrine-Cell Phosphoproteomics
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phosphopeptides were quantified across both biological replicates.
Approximately 10% of proteins had greater than a three-fold
difference in abundance between alpha and beta cells (Table 1),
including known hormones (e.g., insulin, glucagon) and kinases
(Table 2). Exploration of role of these proteins may provide further
insight into the similarities and differences between alpha and beta
cells. Neuropeptide Y and somatostatin, which are known to
inhibit insulin secretion, were expressed at higher levels in beta
cells compared to that in alpha cells [33–35]. Pdx1 and amylin,
which play a key role in several beta-cell functions, were also
expressed at higher levels in beta cells. A comparison of the
phosphoproteomes of alpha and beta cells revealed interesting
differences. For example, while glucagon is expressed at a higher
level in alpha cells, the phosphorylation levels at serines 150 and
152 are higher in beta cells. Further, while insulin is expressed at
higher levels in beta cells, the level of phosphorylation at threonine
51 is higher in alpha cells. We were able to detect known p38
MAP kinase-mediated phosphorylation of transcription factors
MafA and Pdx1 at serine342 and serine 269, respectively [36–38].
The phosphoproteome of alpha cells was not significantly
perturbed in the first hour of BRD7389 treatment, as only 2% of
phosphopeptides showed alteration in levels. However, after five
days of BRD7389 treatment, 9% of phosphopeptides were
upregulated and 5% were downregulated. BRD7389 and
GW8510 inhibit RSK and CDK2 kinases, respectively. Hence,
we expected a decrease in phosphorylation of protein substrates of
Rsk and Cdk2 upon BRD7389 or GW8510 treatment of alpha
cells. Accordingly, we observed a decrease in S6 and EF2
phosphorylation, known substrates of RSK and CDK2, respec-
tively (Table S5 in File S1).
Suppression of Brsk1 and Camkk2 elicits beta cell
features in aTC1 cells
Although several kinases were differentially expressed in alpha
and beta cells, we focused our attention on BRSK1 and
CAMKK2, as they were more highly phosphorylated in alpha
cells compared to beta cells, and in untreated alpha cells compared
to compound-treated cells (Table S6 in File S1). We were unable
to quantify absolute protein levels of these kinases in our proteomic
analyses, but gene expression analysis suggested higher mRNA
levels of Camkk2 in beta cells. Since the role of these proteins in
maintenance of alpha cell state was unknown, we initiated our
investigation by performing siRNA-mediated knock-down of Brsk1
or Camkk2 in aTC1 cells, and determined the expression of alpha
and beta cell-specific genes. Brsk1 and Camkk2 mRNA levels were
reduced by 64% and 85%, respectively, after three-day siRNA
transfection (Figure S6 in File S1). Expression of Camkk2 was also
reduced in siBrsk1-treated cells (53%), suggesting that Brsk1 may
be an upstream activator of Camkk2. Brsk1 knock-down resulted
in the upregulation of the mRNA levels of genes important to
beta-cell identity, including Pdx1, Ngn3, Nkx2.2, and glucokinase
(Gck) (Figure 3A), while Camkk2 down-regulation elicited the
expression of Nkx2.2, Pax4, MafB, and the hormones glucagon
(Gcg) and insulin (Ins2) (Figure 3B). Modest levels of Pdx1 protein
expression were detected by immunofluorescence in siBrsk1- and
siCamkk2-treated cells (Figure S6 in File S1). Consistent with these
observations, STO-609, a Camkk antagonist, and KN62 and
KN93, two selective Ca2+/calmodulin-dependent protein kinase II
(CaMKII) inhibitors, also increased Pdx1 protein expression in
aTC1 cells (Figure 3C).
Since PDX1 protein levels after 3 days of gene knock-down
were detectable but faint, we performed a 10-day knock-down of
Brsk1, Camkk2, and Stk11, an upstream modulator of Brsk1, using
lentiviral shRNAs (Figure 4). When using hairpins targeting Brsk1
and Camkk2, a decrease in these kinases corresponded to a
concomitant increase in Pdx1 mRNA expression (Figure 4A–B).
Hairpins targeting Stk11 (two out of three) also increased Pdx1
expression (Figure 4C). The fact that not all hairpins had the same
effect might reflect off-target silencing effects of these hairpins,
which are part of the limitations of using small-interfering RNAs
Figure 3. Knock-down of Brsk1 and Camkk2 elicit the expression
of key beta cell-specific genes in aTC1 cells. mRNA expression of
beta and alpha cell-specific genes was measured using qPCR after
knock-down of (A) Brsk1 or (B) Camkk2. Fold changes were calculated
compared to untransfected control aTC1 cells, and normalized to
Gapdh expression. Significance was determined by t-test. *p,0.05,
***p,0.005. (C) aTC1 cells transfected with the indicated siRNA, or
treated with the indicated compounds, were analyzed for Pdx1 protein
expression by immunofluorescence. The percentage of Pdx1+ cells was
calculated for each treatment. The significance was determined by t-
test. *p,0.05, **p,0.01, and ***p,0.001.
doi:10.1371/journal.pone.0095194.g003
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[39]. Moreover, individual hairpins to Camkk2, Brsk1, and Stk11
elicited the expression of Pdx1 protein, as detected by immuno-
fluorescence (Figure 4D–S). PDX1-positive cells also co-stained for
insulin when Brsk1 or Camkk2 were knocked down, and more
modestly with knock-down of Stk11 (Figure 4 I,M,Q). Taken
together, our results suggest a role for CAMK family proteins in
maintaining an alpha-cell phenotype.
Discussion
In this study, we compared the transcriptomes, proteomes, and
phosphoproteomes of a pancreatic alpha and beta cell line, with
the aim of identifying new targets whose perturbation may induce
expression of beta-cell markers in alpha cells. Gene-expression
analysis suggested enhanced mitochondrial respiration and
glycolysis in alpha cells compared to beta cells, which we
confirmed experimentally. Furthermore, BRD7389 treatment of
aTC1 lowered mitochondrial respiration and glycolytic activity as
Figure 4. Longer-term lentiviral knockdown of Brsk1 and Camkk2 stimulates PDX1 and insulin protein expression in aTC1 cells. Cells
were infected with lentivirus carrying expression cassettes that encode shRNAs against (A) Brsk1, (B) Camkk2, (C) Stk11, and were selected with
puromycin for 10 days. Pdx1 mRNA expression (white bars) was measured jointly with the expression of each of the shRNA-targeted genes (black
bars). Data represent fold change (in log2 scale), compared to the average of control empty vectors. Data represent mean and standard deviation of
four independent experiments. The significance was determined by t-test. *p,0.05 and **p,0.01. (D–S) Nuclei (blue), insulin (green), and Pdx1 (red)
immunofluorescence, and merged images in 10-day shRNA-expressing aTC1 cells: (D–G) control virus, (H–K) sh1_Camkk2, (L–O) sh1_Brsk1, (P–S)
sh1_Stk11. Scale bar = 100 mm.
doi:10.1371/journal.pone.0095194.g004
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these cells progressed towards a state intermediate between alpha
and beta cells. Beta cell lines, in particular INS-1E, have been
reported to have high proton leak through the mitochondrial
membrane [27], and to have strongly reduced lactate production
[28–30], which is consistent with our observed low spare
respiration and glycolytic capacity. The observed differences in
the mitochondrial respiration and glycolytic activity could also
arise from differences in the growth rate of the alpha and beta cell
lines. Indeed, the beta cell lines used herein have a lower growth
rate (doubling time: 2–3 days) compared to that of aTC1 cells
(doubling time: 1–2 days).
Most lineage-reprogramming efforts involve overexpression of
transcription factors that occur at higher levels in the target cell
type. We have identified several transcription factors that are
enriched in alpha cells and beta cells in our microarray data.
Expected genes were readily identified; for example, Pdx1 plays an
important role in beta cell maturation and function [40].
Interestingly, one of the identified transcription factors, motor
neuron and pancreas homeobox 1 (Mnx1), was recently reported
to play an important role in cell fate determination in zebrafish
[41]. Physiological differences between alpha and beta cells are
also reflected in the annotated gene sets enriched in these cells.
Genes involved in respiration and branched-chain amino acid
were enriched in alpha cells, while the genes associated with
membrane trafficking and lysosomes were enriched in beta cells,
pointing to the relative importance of these biological processes in
the two cell types.
Our prior studies suggested that the inhibition of specific kinases
in alpha cells can lead to expression of key markers of beta cells
[12,13]. Here, we identified two kinases whose knock-down
induced beta-cell markers in alpha cells. BRSK1, also known as
SAD-B, is a serine/threonine kinase strongly expressed in
mammalian forebrain to determine neuronal polarization [42].
BRSK1 is activated both in vitro and in vivo by serine/threonine-
protein kinase 11 (STK11), also known as liver kinase B1 (LKB1),
which plays an important role in the polarization of cortical axons
[43–45]. STK11 is in turn a tumor suppressor and regulator of
energy homeostasis through the activation of AMP-activated
protein kinase (AMPK) [46]. A beta cell-specific deletion of Stk11
causes an increase in beta cell-mass and insulin secretion, effects
mediated by an activation of the mTOR pathway [47]. In
combination with STK11, CAMKK2 (Camkkb) phosphorylates
and activates AMPK [48,49], while in combination with
CAMKK1 (Camkka), it phosphorylates and activates CAMK1
and CAMK4 [50]. Camkk2 null mice are protected from obesity,
insulin resistance, and glucose intolerance [51]. It is noteworthy
that downregulation of Camkk2 in alpha cells increases the
expression of both insulin and glucagon. Directed differentiation of
embryonic stem cells into mature hormone secreting endocrine
cells similarly involve polyhormonal cellular states, often described
as a hallmark of non-fully differentiated cells. Interestingly,
Camkk2 has been reported to play a role in neuronal differen-
tiation[52] and bone remodeling by stimulating osteoblast
formation[53] further supporting the role of this kinase to impact
cell fate decision.
This chemical-genetic and phosphoproteomic study provides
evidence that perturbing the alpha-cell kinome may be an
attractive approach for lineage reprogramming, and points to a
potential role for BRSK1, the CAMK kinase family, and STK11
in determining endocrine-cell identity. Gene silencing and
compound treatments induced mRNA and protein expression of
key beta cell-specific genes, such as Pdx1 and insulin; the LKB1/
BRSK1 and CAMKK2 pathways might converge at the level of
AMPK, as suggested by previous work [46,51]. The presence of
detectable levels of both glucagon and insulin in both aTC1 and
bTC3 cells suggests that these cell lines are not perfect models of
alpha and beta cells. However, we have previously shown that the
protein targets identified from these cell lines using small
molecules, BRD7389 and GW8510, translate in native pancreatic
cells of humans.[12,13] These findings support the notion that
these cell lines can lead to the discovery of novel protein targets
relevant for the primary cells. A potential drawback of our study is
the assumption that phosphorylation of kinases is correlated with
kinase activation. Many examples exist where kinases are
negatively regulated by phosphorylation (e.g., glycogen synthase
kinase 3b). Further studies are required to dissect the opposing
actions of kinases and reprogramming. This may include
delineation of the signaling pathways of these kinases in endocrine
cells, and understanding the signaling role of their phosphorylated
forms. We anticipate that such studies may spur development of
small molecules for lineage reprogramming of alpha cells to
insulin-producing cells.
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